Mechanisms of mature B-cell tumour pathogenesis and of the interplay between host-immunity and these tumours.
Lead Research Organisation:
The Francis Crick Institute
Department Name: Research
Abstract
The incidence of non-Hodgkin's lymphoma (NHL), the majority of which derived from mature B-cells, has virtually doubled in the last two decades in westernized countries. Although improved diagnosis, and AIDS associated lymphomas have contributed to this astonishing escalation of disease incidence, this contribution accounts for no more than 50% of the new cases. Amongst NHL's the Activated B-cell Diffuse Large B-cell Lymphoma (ABC-DLBCL) is the most aggressive and with the poorer clinical prognosis. Multiple Myeloma (MM) is a tumour derived from terminally differentiated mature B-cells (plasma cells) and ranks as the second most common haematological malignancy after NHL, and despite recent advances in chemotherapy it is still an incurable disease. Constitutive NF-kB activity, present in both these tumours interferes with the apoptotic effect of chemotherapy and may account for the poor response to treatment of patients with either ABC-DLBCL or MM. Using sophisticated genetic approaches that include conditional gain-of-function and/or loss-of-function in the mouse, I plan to develop bona-fide pre-clinical models of these diseases in an experimental setting that recapitulates human mature B-cell tumourigenesis as closely as currently possible. These models should prove invaluable for the elucidation of the mechanistic factors in the pathogenesis of these malignancies and provide critical information for the advancement of disease prevention and treatment. In addition to oncogenetic lesions, it has become increasingly clear that host immunity plays a fundamental role in tumour formation and progression. Cancer immune escape is an emerging "Hallmark of Cancer" and regulatory T-cells (Tregs) may play a key role in this context. However, although in solid tumours Tregs aid cancer immune escape their role in haematological malignancies remains controversial, warranting caution when attempting to extrapolate effective treatment strategies in solid tumours. I plan to determine the role of Treg cells in the initiation and progression of human ABC-DLBCL and MM, using the bona fide mouse models for these diseases described above. I expect that inter-species comparative oncogenomics of the tumours arising in mice with their human counterparts will lead to the identification of causative/driver genetic mutations, which could function as prognostic biomarkers and/or therapeutic targets. On other hand, a better understanding of Treg function in the context of haematological malignancies will provide insights on how and when to modulate their activity to stimulate the immune system to control tumour growth.
Technical Summary
Mature B-cell derived tumours are the most frequent human haematological malignancy. Following antigen encounter, mature B-cells can differentiate into plasma cells through a reaction that exposes cells to DNA mutation and recombination in their immunoglobulin genes while rapidly dividing. Infidelity in these processes predisposes genetic lesions, including mutations that activate NF-kB and deregulate c-Myc expression, recurrently observed in the human activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) and in the plasma cell tumour multiple myeloma (MM). However, I found that co-induction of NF-kB signalling and c-Myc expression in mouse B-cells in-vivo, originates MM in 100% of the cases. In contrast, disruption of the plasma cell differentiation regulator Blimp1, promotes the development of ABC-DLBCL, consistent with its frequent inactivation in the human tumour counterpart. This work suggests that a block of B to plasma cell differentiation is required in ABC-DLBCL pathogenesis and I propose to assess alternative mechanisms by which plasma cell differentiation is blocked in the fraction of human ABC-DLBCLs, without Blimp1 inactivation. The final goal is to identify causative genetic mutations through interspecies comparative oncogenomics, which could function as prognostic biomarkers and/or therapeutic targets. In addition to oncogenetic lesions, it has become increasingly clear that host immunity plays a fundamental role in tumour formation and progression and regulatory T-cells (Tregs) may play a key role in this context. However, although in solid tumours Tregs aid cancer immune escape their role in haematological malignancies like ABC-DLBCL and MM remains controversial, warranting caution when attempting to extrapolate effective treatment strategies in solid tumours. I propose to investigate the role of Tregs in these diseases in order to gain insights on how and when to modulate their activity to stimulate the immune system to control tumour growth.
Planned Impact
Treatment of mature B-cell derived cancers, the most common type of human haematological malignancy overall, is still a serious challenge in medicine. The incidence of these tumours has virtually doubled in the last two decades in westernized countries. Although improved diagnosis, and AIDS associated lymphomas have contributed to this astonishing escalation of disease incidence, this contribution accounts for no more than 50% of the new cases. Amongst NHL's the Activated B-cell Diffuse Large B-cell Lymphoma (ABC-DLBCL) is the most aggressive and with the poorer clinical prognosis. Multiple Myeloma (MM), a tumour derived from terminally differentiated B-cells, is the second most common haematological malignancy after NHL and despite recent advances in chemotherapy, it is still an incurable disease. The elucidation of the mechanistic factors in the pathogenesis of these malignancies is critical for the advancement of disease prevention and treatment. The current project aims to generate bona fide stochastic models of ABC-DLBCL and MM with potential pre-clinical interest, by recapitulating the gene/pathway lesions associated with these human B-cell tumour subtypes.
- I predict that achievement of the proposed aims to generate significant interest in the mainstream media.
- The investigator aims in addition to deliver a series of after school workshops to local students on the nature of cancer and how our immune system may help fight cancer. The proposed research would be important to provide additional insights and information for the success of these public sessions.
It is now clear that the study of tumour development cannot be confined to the intrinsic cellular mechanisms of oncogenic transformation, and has to take into account the interaction of pre-tumour and tumour cells with their cellular microenvironment. This includes cells of the immune system, for which cumulating evidence suggests a fundamental role in tumour suppression, leading to the establishment of the escape of tumour cells from the immune system as an emerging "Hallmark of Cancer". However, most oncology drugs are tested in systems, so-called Xenograft models, which do not take into account the contribution of the immune system in cancer development. This has been suggested to be major cause for the failure rate of cancer related drugs in clinical trials.
- The development of pre-clinical mouse models of ABC-DLBCL and MM could be applied to enhance the discovery of drugs effective in killing tumour cells in an experimental setting that recapitulates human mature B-cell tumourigenesis as closely as currently possible.
- It is expected that these models may help biotechnology and pharmaceutical company researchers to be more productive in the development of effective oncology drugs.
- I predict that achievement of the proposed aims to generate significant interest in the mainstream media.
- The investigator aims in addition to deliver a series of after school workshops to local students on the nature of cancer and how our immune system may help fight cancer. The proposed research would be important to provide additional insights and information for the success of these public sessions.
It is now clear that the study of tumour development cannot be confined to the intrinsic cellular mechanisms of oncogenic transformation, and has to take into account the interaction of pre-tumour and tumour cells with their cellular microenvironment. This includes cells of the immune system, for which cumulating evidence suggests a fundamental role in tumour suppression, leading to the establishment of the escape of tumour cells from the immune system as an emerging "Hallmark of Cancer". However, most oncology drugs are tested in systems, so-called Xenograft models, which do not take into account the contribution of the immune system in cancer development. This has been suggested to be major cause for the failure rate of cancer related drugs in clinical trials.
- The development of pre-clinical mouse models of ABC-DLBCL and MM could be applied to enhance the discovery of drugs effective in killing tumour cells in an experimental setting that recapitulates human mature B-cell tumourigenesis as closely as currently possible.
- It is expected that these models may help biotechnology and pharmaceutical company researchers to be more productive in the development of effective oncology drugs.
People |
ORCID iD |
Dinis Calado (Principal Investigator / Fellow) |
Publications
Flümann R
(2023)
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
in Blood cancer discovery
Lionarons DA
(2019)
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.
in Cancer cell
Ottina E
(2018)
Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models.
in Cancer immunology research
Kallemeijn WW
(2019)
Validation and Invalidation of Chemical Probes for the Human N-myristoyltransferases.
in Cell chemical biology
Coffre M
(2016)
miRNAs Are Essential for the Regulation of the PI3K/AKT/FOXO Pathway and Receptor Editing during B Cell Maturation.
in Cell reports
Zhang B
(2015)
An oncogenic role for alternative NF-?B signaling in DLBCL revealed upon deregulated BCL6 expression.
in Cell reports
Morini MF
(2018)
VE-Cadherin-Mediated Epigenetic Regulation of Endothelial Gene Expression.
in Circulation research
Kuczynski EA
(2022)
A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.
in EMBO molecular medicine
Nakagawa R
(2021)
Positive Selection in the Light Zone of Germinal Centers.
in Frontiers in immunology
Knolle MD
(2018)
MicroRNA-155 Protects Group 2 Innate Lymphoid Cells From Apoptosis to Promote Type-2 Immunity.
in Frontiers in immunology
Alberts E
(2021)
Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells.
in Frontiers in molecular biosciences
Brown PJ
(2016)
N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
in Haematologica
Eswaran J
(2015)
The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.
in Leukemia
Maybury BD
(2021)
Generation and Surgical Analysis of Genetic Mouse Models to Study NF-?B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.
in Methods in molecular biology (Clifton, N.J.)
Lattke M
(2017)
Transient IKK2 activation in astrocytes initiates selective non-cell-autonomous neurodegeneration.
in Molecular neurodegeneration
Lazarus KA
(2018)
BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma.
in Nature communications
Frye M
(2018)
Matrix stiffness controls lymphatic vessel formation through regulation of a GATA2-dependent transcriptional program.
in Nature communications
Pyrzynska B
(2018)
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.
in Oncoimmunology
Nakagawa R
(2021)
Permissive selection followed by affinity-based proliferation of GC light zone B cells dictates cell fate and ensures clonal breadth.
in Proceedings of the National Academy of Sciences of the United States of America
D'Avola A
(2022)
PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.
in The Journal of clinical investigation
Toboso-Navasa A
(2020)
Restriction of memory B cell differentiation at the germinal center B cell positive selection stage.
in The Journal of experimental medicine
Description | Blood Cancer UK Grant Advisory Committee |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Grant evaluation. The grants provide salary for postdoctoral fellowships. |
URL | https://bloodcancer.org.uk/ |
Description | Blood Cancer UK Grant Advisory Committee |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Grant evaluation. The grants provide salary for postdoctoral fellowships. |
URL | https://bloodcancer.org.uk/ |
Description | Blood Cancer UK Grant Advisory Committee |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Grant evaluation and discussion; these grants provide salary for training of postdoctoral research fellows. |
URL | https://bloodcancer.org.uk/ |
Description | Blood Cancer UK Grant Advisory Committee |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Grant evaluation. The grants provide salary for postdoctoral fellowships. |
URL | https://bloodcancer.org.uk/ |
Description | CRUK Discovery Research Committee |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Grant evaluation and discussion; these grants provide salary for training of postdoctoral research fellows. |
URL | https://www.cancerresearchuk.org/ |
Description | Wellcome Trust Sir Henry Dale Fellowship Advisory Committee |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Grant evaluation and discussion; these grants provide salary for training of postdoctoral research fellows. |
URL | https://wellcome.org/ |
Description | Crosstalk Between Tumour and Draining Lymph Nodes and its Impact on Triple-Negative Breast Cancer |
Amount | £793,000 (GBP) |
Funding ID | MR/W025221/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2022 |
End | 08/2025 |
Description | Development of a Model System to Study Diffuse Large B Cell Lymphoma Clonal Evolution |
Amount | £249,999 (GBP) |
Organisation | Leuka |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2019 |
End | 12/2021 |
Description | Early detection and intervention: Understanding the mechanisms of transformation and hidden resistance of incurable haematological malignancies |
Amount | £4,712,710 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 10/2018 |
End | 09/2023 |
Description | H2020-EU.4.b. - Twinning of research institutions |
Amount | € 1,000,000 (EUR) |
Funding ID | 692180 |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 01/2016 |
End | 12/2018 |
Description | Heterogeneity of Plasma Cells and of its Survival Niche in the context of Ageing |
Amount | £49,000 (GBP) |
Funding ID | AIS2110\9 |
Organisation | The Dunhill Medical Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2022 |
End | 04/2023 |
Description | Hitting back at double/triple-hit lymphoma: modelling mechanisms of therapy resistance |
Amount | £249,472 (GBP) |
Funding ID | 22012 |
Organisation | Blood Cancer UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2022 |
End | 08/2025 |
Description | Mechanisms of cancer therapy resistance and evolution |
Amount | £190,000 (GBP) |
Funding ID | N/A |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2022 |
End | 08/2025 |
Description | Physiological and Pathological Plasma Cell Niches in the Context of NF-kB Pathway Activity |
Amount | € 70,800 (EUR) |
Funding ID | EMBO ALTF 836-2021 |
Organisation | European Molecular Biology Organisation |
Sector | Charity/Non Profit |
Country | Germany |
Start | 01/2022 |
End | 12/2024 |
Title | Generation and Surgical Analysis of Genetic Mouse Models to Study NF-?B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma |
Description | Enforced activation of NF-?B signaling can be achieved by constitutive NF-?B-inducing kinases, IKK2 and NIK, or via lymphoma-associated mutants of MYD88, CARD11, and CD79B. In order to model Diffuse Large B Cell Lymphoma (DLBCL) in mice, conditional alleles for these proteins are combined with alleles targeting Cre recombinase expression in mature B cells. However, unopposed NF-?B signaling promotes plasmablast differentiation, and as a consequence the model system must be complemented with further mutations that block differentiation, such as Prdm1/BLIMP1 inactivation or overexpression of BCL6. Here, we describe the currently available tools for DLBCL models in mice and their relative advantages and drawbacks. Furthermore, we describe methods to monitor lymphomagenesis, using ultrasound tomography of the spleen, and the technique of partial splenectomy surgery with recovery. These powerful techniques allow paired comparison of individual lymphoma cases before and after interventions, including therapies, and to study the evolution of lymphoma over time. NF-?B activation also promotes widespread nodal involvement with lymphoma and we describe the post-mortem dissection of major nodal groups. |
Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
Year Produced | 2021 |
Provided To Others? | Yes |
Impact | These powerful techniques allow paired comparison of individual lymphoma cases before and after interventions, including therapies, and to study the evolution of lymphoma over time. |
URL | https://pubmed.ncbi.nlm.nih.gov/34236648/ |
Description | Research of lymphoma therapy resistance and evolution |
Organisation | Queen Mary University of London |
Department | Barts Cancer Institute |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generation of genetically defined mouse models to study therapy resistance |
Collaborator Contribution | Analysis of human cancer samples to study therapy resistance |
Impact | Blood Cancer UK Funding Publication |
Start Year | 2019 |
Description | Research of lymphoma therapy resistance and evolution |
Organisation | University of Göttingen |
Country | Germany |
Sector | Academic/University |
PI Contribution | Generation of genetically defined mouse models to study therapy resistance |
Collaborator Contribution | Analysis of human cancer samples to study therapy resistance |
Impact | Blood Cancer UK Funding |
Start Year | 2021 |
Description | Research of lymphoma therapy resistance and evolution |
Organisation | University of Leeds |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generation of genetically defined mouse models to study therapy resistance |
Collaborator Contribution | Analysis of human cancer samples to study therapy resistance |
Impact | Blood Cancer UK Funding |
Start Year | 2021 |
Description | Research of lymphoma therapy resistance and evolution |
Organisation | University of Southampton |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generation of genetically defined mouse models to study therapy resistance |
Collaborator Contribution | Analysis of human cancer samples to study therapy resistance |
Impact | Blood Cancer UK Funding |
Start Year | 2021 |
Description | Role of B cell Populations in Triple-Negative Breast Cancer |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We developed and implemented mouse models of triple negative breast cancer. |
Collaborator Contribution | Analysis |
Impact | Grant funding from UKRI-MRC, Boehringer Ingelheim |
Start Year | 2022 |
Title | NMT inhibition new uses |
Description | NMT inhibition new uses |
IP Reference | P029833GB |
Protection | Patent granted |
Year Protection Granted | 2019 |
Licensed | Commercial In Confidence |
Impact | This patent formed in part the basis for venture capital investment in a new company Myrix. |
Company Name | MYRICX PHARMA LIMITED |
Description | Translating world leading research in NMT into novel medicines Myricx Pharma ("Myricx") is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across viral and other diseases. The Company is based on novel discoveries from the research laboratories of its co-founders, Prof Ed Tate, Dr Roberto Solari and Dr Andrew Bell. The research teams identified that inhibition of NMT, an enzyme involved in myristoylation of certain proteins, results in specific cancer cell killing via an unexpected and unique mechanism. This breakthrough discovery reveals that NMT inhibitors are proving to be highly effective in the treatment of MYC-driven cancer models. Until now MYC was considered to be undruggable. Myricx is now prioritising the development of potent small-molecule inhibitors with the aim of building a proprietary pipeline of targeted cancer therapies. |
Year Established | 2019 |
Impact | Leading the translation of NMT science into promising new precision medicines Myristoylation, is a lipid modification to a specific group of proteins that allows them to interact with other proteins or membranes. It is catalysed by the enzyme N-myristoyltransferase (NMT) which introduces irreversible changes to human proteins and is known to be involved in a range of diseases including cancer, inflammatory conditions, epilepsy and Alzheimer's disease. Myricx is based on over 15 years of research focused on the function of NMT and on gaining a deep understanding of its enzymology and structure, as well as biology. Myristoylation plays vital roles in protein-protein interactions, targeting proteins to cytoplasmic and plasma membranes, and regulating cellular signalling pathways in several biological processes. |
Website | https://myricxpharma.com/ |
Description | 19th International Conference on Lymphatic Tissues and Germinal Centres in Immune Reactions (GCC) - Venice Italy |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Work presentation |
Year(s) Of Engagement Activity | 2017 |
Description | 21st Congress of the European Hematology Association (EHA), Denmark |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited Educational Session |
Year(s) Of Engagement Activity | 2016 |
URL | https://www.ehaweb.org/congress-and-events/21st-congress/key-information-3/ |
Description | 2nd UK - Germany Lymphoma retreat - Peak District, UK |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | Discussion or lymphoma research and therapy |
Year(s) Of Engagement Activity | 2017 |
Description | 3i Consortium meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | Presentation on genetics tools used in the laboratory and how to generated novel model systems. |
Year(s) Of Engagement Activity | 2016 |
URL | http://www.immunophenotype.org/ |
Description | 6th Translational Research Conference: Lymphoid Malignancies |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Research presentation and discussion |
Year(s) Of Engagement Activity | 2021 |
URL | https://lymphoid-2021.esh.live/ |
Description | A talk or presentation - Southampton University |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Presentation of research and discussion |
Year(s) Of Engagement Activity | 2022 |
Description | AACR International Meeting on Advances in Malignant Lymphoma |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | International research meeting in lymphoma. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.aacr.org/meeting/advances-in-malignant-lymphoma-2020/ |
Description | ASH annual meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Work presentation and discussion |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.hematology.org/meetings/annual-meeting |
Description | B cells in cancer - University of North Carolina at Chapel Hill (UNC Lineberg)/King's College |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | A team of specialists presented their work in B cells. |
Year(s) Of Engagement Activity | 2020 |
Description | BSI Yorkshire group symposium: York, UK; June 2018. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Work presentation and discussion. |
Year(s) Of Engagement Activity | 2018 |
Description | Bloodwise Grantholders meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Undergraduate students |
Results and Impact | Discussion of research data. |
Year(s) Of Engagement Activity | 2019 |
Description | British Society for Immunology |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Work presentation and discussion |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.immunology.org/events/british-society-for-immunology-congress-2021 |
Description | British Society for Immunology 2017 - Brighton, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Work presentation / discussion |
Year(s) Of Engagement Activity | 2017 |
Description | CRUK CoL Theme 2 workshop |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on research data. |
Year(s) Of Engagement Activity | 2019 |
Description | CRUK accelerator award seminar |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on research presentation. |
Year(s) Of Engagement Activity | 2019 |
Description | Crick Cancer Get Together, Wellcome Trust, London UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of work from the laboratory |
Year(s) Of Engagement Activity | 2016 |
Description | Crick Cancer Research Symposium |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Annual Crick symposium on Cancer Research. |
Year(s) Of Engagement Activity | 2020 |
URL | https://www.crick.ac.uk/whats-on/crick-cancer-research-symposium-0 |
Description | DLBCL Mini Symposium 2018: Cologne, Germany; February 2018 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Lymphoma Symposium - scientific audience |
Year(s) Of Engagement Activity | 2018 |
Description | European B Cell Network |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion of research data. |
Year(s) Of Engagement Activity | 2019 |
Description | Follicular Lymphoma Meeting - North Berwick, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | International collaborations in Follicular Lymphoma |
Year(s) Of Engagement Activity | 2017 |
Description | John Humphrey Seminar Series - London, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Presentation of work |
Year(s) Of Engagement Activity | 2017 |
Description | KCL Advanced Therapies seminar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on research presentation. |
Year(s) Of Engagement Activity | 2019 |
Description | Keystone Conference - NF-kappaB and MAP Kinase Signaling in Inflammation, Canada, |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited plenary lecture |
Year(s) Of Engagement Activity | 2016 |
URL | https://www.keystonesymposia.org/index.cfm?e=Web.Meeting.Summary&meetingid=1370&subTab=summary |
Description | King's Genetics Department |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion of research data. |
Year(s) Of Engagement Activity | 2019 |
Description | London Immunology Group (BSI) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of work from the laboratory |
Year(s) Of Engagement Activity | 2016 |
Description | Lymphoma Biology Symposium, Cambridge, UK; July 2018. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of work and discussion |
Year(s) Of Engagement Activity | 2018 |
Description | Lymphoma Programme Seminar - London, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Study participants or study members |
Results and Impact | Discussion on tissue bank and future collaborations |
Year(s) Of Engagement Activity | 2017 |
Description | Mini-Symposium on Advances in Immuno-Oncology - Trieste |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Undergraduate students |
Results and Impact | Presentation of work from the laboratory |
Year(s) Of Engagement Activity | 2016 |
Description | Molecular Haemopoiesis 20, - London, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Work presentation / discussion |
Year(s) Of Engagement Activity | 2017 |
Description | Munster University |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on research data. |
Year(s) Of Engagement Activity | 2019 |
Description | Portuguese Society for Immunology |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on research data. |
Year(s) Of Engagement Activity | 2019 |
Description | Presentation on research performed at the Cancer Research UK, London Research Institute |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Our studies aim to understand the pathogenesis of cancer, something not possible to achieve without the use of living model organisms. In my presentation I aimed to explain the needs and benefits of using mouse models in cancer research, highlighting how in the laboratory we implement experimental protocols leading to the reduction in the number of animals used, how we refine procedures to obtain the best possible information from each used animal, as well as explaining how specific pieces of information may be possible to obtain without the need to use animal models. Better understanding of the need of animal models in cancer research, as displayed by the comments and feedback of the attendees. |
Year(s) Of Engagement Activity | 2013,2014 |
Description | STREAM Consortium Meeting seminar |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on research outputs. |
Year(s) Of Engagement Activity | 2018 |
Description | STREAM Consortium Meeting: London, UK; November 2018. |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Meeting with consortium members and discusion |
Year(s) Of Engagement Activity | 2018 |
Description | STREAM Consortium Meeting: Oslo, Norway |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Meeting of the consortium with work presentations made for scientific audience |
Year(s) Of Engagement Activity | 2018 |
Description | STREAM summer school, Warsaw |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation on a summer school |
Year(s) Of Engagement Activity | 2016 |
Description | Seminar at the Pasteur Institute - Paris, France |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Presentation of research |
Year(s) Of Engagement Activity | 2017 |
Description | Signal Transduction in Health and Disease - London, UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Work presentation / discussion |
Year(s) Of Engagement Activity | 2017 |
Description | Stem Cells @ Lunch - London, UK; June 2017 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Presentation of work |
Year(s) Of Engagement Activity | 2017 |
Description | TwinnToInfect Spring School on Infection and Immunity: Lisbon, Portugal; March 2018. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Presentation and discussion of work |
Year(s) Of Engagement Activity | 2018 |
Description | UK - Germany Lymphoma Meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Research presentation and discussion |
Year(s) Of Engagement Activity | 2022 |
Description | UK - Germany Lymphoma meeting: Peak District, UK; April 2018. |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Presentation of work and discussion |
Year(s) Of Engagement Activity | 2018 |
Description | Ulm University - Germany |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of work from the laboratory |
Year(s) Of Engagement Activity | 2016 |
Description | University of Birmingham - UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation of work from the laboratory |
Year(s) Of Engagement Activity | 2016 |
Description | Weill Cornell Hematologic Malignancy Lecture Series |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Discussion on research data. |
Year(s) Of Engagement Activity | 2019 |